Dr. Axel Hoos, Md, PhD, is a physician-scientist, biopharma leader and entrepreneur with broad experience in drug development and building life science organizations. Most recently he served as CEO of Scorpion Therapeutics, focusing on Precision Oncology 2.0 for optimally designed small molecule cancer medicines. Scorpion was acquired by Eli Lilly for $2.5B. Previously, Dr. Hoos served as Senior Vice President, R&D Governance Chair, and Therapeutic Area (TA) Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). Prior to GSK, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he and his team developed YERVOY® (Ipilimumab), the first immune checkpoint inhibitor drug. Dr. Hoos also served as Executive Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), a Global Health organization, where he oversaw its organizational re-structuring and renewal of R&D strategy. Further he was Co-founder and Director on the Board of Imugene, an Australian biotech company, Director on the Boards of TCR2, a cell therapy company, and NextPoint Therapeutics, an Immuno-Oncology company, Co-Director of the Cancer Immunotherapy Consortium (CIC), Scientific Advisory Board Member of the Cancer Research Institute (CRI), and Co-Founder and Executive Committee member of the PACT initiative of the Biden Cancer Moonshot.